Endogenous Myc maintains the tumor microenvironment

Genes and Development

Volumn 25, Issue 9, 2011, Pages 907-916

  Sodir, Nicole M ^a,b   Swigart, Lamorna Brown ^a,b   Karnezis, Anthony N ^a,b   Hanahan, Douglas ^c   Evan, Gerard I ^a,b,d   Soucek, Laura ^a,b,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c EPFL   (Switzerland)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

Author keywords

Microenvironment; Myc inhibition; Pancreas; Therapeutics; Tumor

Indexed keywords

MYC PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HUMAN; NONHUMAN; PANCREAS ISLET CELL TUMOR; PRIORITY JOURNAL; SIMIAN VIRUS 40; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOXYCYCLINE; GENE EXPRESSION REGULATION, NEOPLASTIC; GTPASE-ACTIVATING PROTEINS; MICE; NEUROENDOCRINE TUMORS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MYC; REPRESSOR PROTEINS; SIMIAN VIRUS 40; TUMOR MICROENVIRONMENT;

SIMIAN VIRUS 40;

EID: 79955403911     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.2038411     Document Type: Article

References (29)

1. Ahuja D, Saenz-Robles MT, Pipas JM. 2005. SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene 24: 7729-7745.
2. Baskar JF, Smith PP, Nilaver G, Jupp RA, Hoffmann S, Peffer NJ, Tenney DJ, Colberg-Poley AM, Ghazal P, Nelson JA. 1996. The enhancer domain of the human cytomegalovirus major immediate-early promoter determines cell type-specific expression in transgenic mice. J Virol 70: 3207-3214.
3. Bergers G, Hanahan D. 2008. Modes of resistance to antiangiogenic therapy. Nat Rev Cancer 8: 592-603.
4. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, et al. 2000. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2: 737-744.
5. Brekken RA, Huang X, King SW, Thorpe PE. 1998. Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res 58: 1952-1959.
6. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. 2005. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8: 299-309.
7. Christofori G, Hanahan D. 1994. Molecular dissection of multistage tumorigenesis in transgenic mice. Semin Cancer Biol 5: 3-12.
8. Coussens LM, Fingleton B, Matrisian LM. 2002. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295: 2387-2392.
9. Fingleton B. 2003. Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects. Expert Opin Ther Targets 7: 385-397.
10. Folkman J, Watson K, Ingber D, Hanahan D. 1989. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58-61.
11. Furth PA, Hennighausen L, Baker C, Beatty B, Woychick R. 1991. The variability in activity of the universally expressed human cytomegalovirus immediate early gene 1 enhancer/ promoter in transgenic mice. Nucleic Acids Res 19: 6205-6208.
12. Goldsworthy SM, Stockton PS, Trempus CS, Foley JF, Maronpot RR. 1999. Effects of fixation on RNA extraction and amplification from laser capture microdissected tissue. Mol Carcinog 25: 86-91.
13. Hanahan D. 1985. Heritable formation of pancreatic b-cell tumours in transgenic mice expressing recombinant insulin/ simian virus 40 oncogenes. Nature 315: 115-122.
14. Kothary R, Barton SC, Franz T, Norris ML, Hettle S, Surani MA. 1991. Unusual cell specific expression of a major human cytomegalovirus immediate early gene promoter-lacZ hybrid gene in transgenic mouse embryos. Mech Dev 35: 25-31.
15. Luzzi V, Holtschlag V, Watson MA. 2001. Expression profiling of ductal carcinoma in situ by laser capture microdissection and high-density oligonucleotide arrays. Am J Pathol 158: 2005-2010.
16. Meyer N, Penn LZ. 2008. Reflecting on 25 years with MYC. Nat Rev Cancer 8: 976-990.
17. Miller KD, Sweeney CJ, Sledge GW Jr. 2005. Can tumor angiogenesis be inhibited without resistance? EXS 2005: 95-112.
18. Nozawa H, Chiu C, Hanahan D. 2006. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci 103: 12493-12498.
19. Pelengaris S, Littlewood T, Khan M, Elia G, Evan G. 1999. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell 3: 565-577.
20. Pelengaris S, Khan M, Evan GI. 2002. Suppression of Mycinduced apoptosis in b cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109: 321-334.
21. Sablina AA, Hahn W. 2008. SV40 small T antigen and PP2A phosphatase in cell transformation. Cancer Metastasis Rev 27: 137-146.
22. Shchors K, Shchors E, Rostker F, Lawlor ER, Brown-Swigart L, Evan GI. 2006. The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1b. Genes Dev 20: 2527-2538.
23. Shojaei F, Singh M, Thompson JD, Ferrara N. 2008. Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci 105: 2640-2645.
24. Singhal G, Kadeppagari RK, Sankar N, Thimmapaya B. 2008. Simian virus 40 large T overcomes p300 repression of c-Myc. Virology 377: 227-232.
25. Soucek L, Helmer-Citterich M, Sacco A, Jucker R, Cesareni G, Nasi S. 1998. Design and properties of a Myc derivative that efficiently homodimerizes. Oncogene 17: 2463-2472.
26. Soucek L, Jucker R, Panacchia L, Ricordy R, Tato F, Nasi S. 2002. Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis. Cancer Res 62: 3507-3510.
27. Soucek L, Nasi S, Evan GI. 2004. Omomyc expression in skin prevents Myc-induced papillomatosis. Cell Death Differ 11: 1038-1045.
28. Soucek L, Lawlor E, Soto D, Shchors K, Swigart L, Evan G. 2007. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 13: 1211-1218.
29. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, Karnezis AN, Swigart LB, Nasi S, Evan GI. 2008. Modelling Myc inhibition as a cancer therapy. Nature 455: 679-683.